Esperion Therapeutics Inc... (ESPR)
NASDAQ: ESPR
· Real-Time Price · USD
3.30
0.40 (13.79%)
At close: Oct 03, 2025, 3:59 PM
3.28
-0.61%
After-hours: Oct 03, 2025, 07:51 PM EDT
13.79% (1D)
| Bid | 2.38 |
| Market Cap | 665.11M |
| Revenue (ttm) | 268.13M |
| Net Income (ttm) | -96.09M |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | -6.11 |
| Forward PE | -96.67 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 3.84 |
| Volume | 18,878,601 |
| Avg. Volume (20D) | 5,887,677 |
| Open | 3.06 |
| Previous Close | 2.90 |
| Day's Range | 2.97 - 3.38 |
| 52-Week Range | 0.69 - 3.94 |
| Beta | 0.96 |
| Ex-Dividend Date | n/a |
About ESPR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ESPR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ESPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEsperion Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+8.72%
Esperion Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
7 months ago
+12.03%
Esperion Therapeutics shares are trading higher after the company reported better than expected Q4 FY24 earnings.
2 months ago · fool.com
Esperion (ESPR) Q2 Revenue Jumps 12%Esperion (ESPR) Q2 Revenue Jumps 12%
2 months ago · seekingalpha.com
Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call TranscriptEsperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Off...
